相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
Rory M. Shallis et al.
BLOOD ADVANCES (2023)
Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions
Afaf E. G. Osman et al.
BLOOD REVIEWS (2021)
Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
Yundeok Kim et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2021)
Low-dose dasatinib: when less can be more
Philip Crawford Amrein
Lancet Haematology (2021)
Chronic myeloid leukaemia
Jorge Cortes et al.
LANCET (2021)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Measurement Properties of Existing Patient-Reported Outcome Measures on Medication Adherence: Systematic Review
Yu Heng Kwan et al.
JOURNAL OF MEDICAL INTERNET RESEARCH (2020)
How I treat chronic myeloid leukemia in children and adolescents
Nobuko Hijiya et al.
BLOOD (2019)
Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia
Adi J. Klil-Drori et al.
CANCER (2019)
CDC Grand Rounds: Improving Medication Adherence for Chronic Disease Management - Innovations and Opportunities
Andrea B. Neiman et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2017)
Factors Influencing Adherence to Imatinib in Indian Chronic Myeloid Leukemia Patients: A Cross-Sectional Study
Jyotsna Kapoor et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2015)
Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase
Annie Guerin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges
Lucien Noens et al.
HAEMATOLOGICA (2014)
Monitoring Molecular Response to Tyrosine Kinase Therapy in Chronic Myelogenous Leukemia
Jerald P. Radich
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)
Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians
Meri Kekale et al.
PATIENT PREFERENCE AND ADHERENCE (2014)
Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib
Stuart L. Goldberg et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Medication Adherence and Health Care Utilization in Pediatric Chronic Illness: A Systematic Review
Meghan E. McGrady et al.
PEDIATRICS (2013)
Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia
Annie Guérin et al.
JOURNAL OF MEDICAL ECONOMICS (2013)
Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia
Elias J. Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia
Adam Gater et al.
LEUKEMIA RESEARCH (2012)
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
Amr R. Ibrahim et al.
BLOOD (2011)
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
Lucien Noens et al.
BLOOD (2009)
Treatment interruptions and non-adherence with imatinib and associated healthcare costs - A retrospective analysis among managed care patients with chronic myelogenous leukaemia
Theodore Darkow et al.
PHARMACOECONOMICS (2007)
分享论文
